Chemistry:Norvinisterone
 | |
| Clinical data | |
|---|---|
| Trade names | Neoprogestin, Nor-Progestelea |
| Other names | Vinylnortestosterone; SC-4641; 17α-Vinyl-19-nortestosterone; 17α-Vinylestr-4-en-17β-ol-3-one |
| Routes of administration | By mouth |
| Drug class | Progestogen; Progestin; Androgen; Anabolic steroid |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C20H28O2 |
| Molar mass | 300.442 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 169 to 171 °C (336 to 340 °F) [1] |
| |
| |
Norvinisterone, sold under the brand names Neoprogestin and Nor-Progestelea, is a progestin and androgen/anabolic steroid (AAS) medication which was used in Europe but is now no longer marketed.[1][2][3][4][5] It is taken by mouth.
Norvinisterone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone.[2] It has androgenic activity.[6]
Norvinisterone was synthesized in 1953.[2] It is no longer available.[7]
Medical uses
Norvinisterone was used in hormonal contraception to prevent pregnancy.[1][3]
Pharmacology
Pharmacodynamics
Norvinisterone is a progestogen.[2][8][5] It appears to be quite androgenic, with about one-third and one-fifth of the androgenic and anabolic activity, respectively, of nandrolone in animal bioassays.[6] However, it has also been reported to have little anabolic activity.[9]
Chemistry
Norvinisterone, also known as 17α-vinyl-19-nortestosterone or as 17α-vinylestr-4-en-17β-ol-3-one, is a synthetic estrane steroid and a derivative of testosterone and 19-nortestosterone.[2] Analogues of norvinisterone include the progestin norgesterone and the AAS vinyltestosterone.[2]
History
Norvinisterone was synthesized in 1953[2] and was studied in humans by 1960.[8]
Society and culture
Generic names
Norvinisterone is the generic name of the drug and its INN.[2] It is also known as vinylnortestosterone and is known by its developmental code name SC-4641.[2][1]
Brand names
Norvinisterone was marketed under the brand names Neoprogestin and Nor-Progestelea by Syntex.[2][1]
Availability
Norgesterone is no longer marketed and hence is no longer available in any country.[7]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "6637: Norvinisterone". Merck Index (11th ed.). Rahway, N.J.: Merck & Co.. 1989. ISBN 978-0-911910-28-5.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014. pp. 889–. ISBN 978-1-4757-2085-3. https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA889.
- ↑ 3.0 3.1 Concise Dictionary of Biomedicine and Molecular Biology. CRC Press. 21 December 2001. pp. 774–. ISBN 978-1-4200-4130-9. https://books.google.com/books?id=Y4DLBQAAQBAJ&pg=PA774.
- ↑ Chemikalien und Drogen Teil A: N-Q. Springer Berlin Heidelberg. 12 March 2013. pp. 274–. ISBN 978-3-642-65035-2. https://books.google.com/books?id=4TWnBgAAQBAJ&pg=PA274.
- ↑ 5.0 5.1 "Relationship between the anesthetic and gestagenic action and estrous behavior-inducing activity of different progestins". Endocrinology 81 (2): 369–374. August 1967. doi:10.1210/endo-81-2-369. PMID 4952012.
- ↑ 6.0 6.1 "The myotrophic and androgenic effects of 17-ethyl-19-nortestosterone and related compounds". Endocrinology 58 (5): 567–572. May 1956. doi:10.1210/endo-58-5-567. PMID 13317831.
- ↑ 7.0 7.1 http://www.micromedexsolutions.com/micromedex2/[yes|permanent dead link|dead link}}]
- ↑ 8.0 8.1 "[Clinical trial of a new luteoid: norvinisterone]" (in es). El Dia Medico 32: 194–197. March 1960. PMID 14421807.
- ↑ "Structure-activity relationships of anabolic steroids: role of the 19-methyl group". The Journal of Clinical Endocrinology and Metabolism 19 (8): 921–935. August 1959. doi:10.1210/jcem-19-8-921. PMID 14442516.
{{Navbox
| name = Androgens and antiandrogens | title = Androgens and antiandrogens | state = collapsed | listclass = hlist | groupstyle = text-align:center;
| group1 = Androgens
(incl. AAS)
| list1 =
| group2 = Antiandrogens | list2 = {{Navbox|child | groupstyle = text-align:center; | groupwidth = 9em;
| group1 = AR antagonists | list1 =
- Steroidal: Abiraterone acetate
- Canrenone
- Chlormadinone acetate
- Cyproterone acetate
- Delmadinone acetate
- Dienogest
- Drospirenone
- Medrogestone
- Megestrol acetate
- Nomegestrol acetate
- Osaterone acetate
- Oxendolone
- Potassium canrenoate
- Spironolactone
- Nonsteroidal: Apalutamide
- Bicalutamide
- Cimetidine
- Darolutamide
- Enzalutamide
- Flutamide
- Ketoconazole
- Nilutamide
- Seviteronel†
- Topilutamide (fluridil)
| group2 = Steroidogenesis| list2 =
inhibitors
| 5α-Reductase | |
|---|---|
| Others |
| group3 = Antigonadotropins | list3 =
- D2 receptor antagonists (prolactin releasers) (e.g., domperidone, metoclopramide, risperidone, haloperidol, chlorpromazine, sulpiride)
- Estrogens (e.g., bifluranol, [[diethylstilbestrol, estradiol, estradiol esters, ethinylestradiol, ethinylestradiol sulfonate, paroxypropione)
- GnRH agonists (e.g., leuprorelin)
- GnRH antagonists (e.g., cetrorelix)
- Progestogens (incl., chlormadinone acetate, [[cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, [[Chemistry:Medroxyprogesterone medroxyprogesterone acetate, Chemistry:Megestrol acetate|megestrol acetate]])
| group4 = Others | list4 =
- Androstenedione immunogens: Androvax (androstenedione albumin)
- Ovandrotone albumin (Fecundin)
}}
| liststyle = background:#DDDDFF;| list3 =
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Androgen receptor modulators
- Estrogens and antiestrogens
- Progestogens and antiprogestogens
- List of androgens/anabolic steroids
}}
 |  |
